Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

128.15USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$128.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
434,398
52-wk High
$147.63
52-wk Low
$35.98

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $12,601.09
Shares Outstanding(Mil.): 98.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran

* U.S. Food and Drug Administration (FDA) grants Alnylam breakthrough therapy designation (BTD) for Patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis with polyneuropathy

Nov 20 2017

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

Nov 16 2017

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis

Nov 16 2017

BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug

* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis

Nov 13 2017

BRIEF-Alnylam announces proposed public offering to raise about $675 mln

* Alnylam Pharmaceuticals announces proposed public offering of $675,000,000 of common stock

Nov 13 2017

BRIEF-Alnylam announces successful outcome following FDA type A meeting

* Alnylam announces successful outcome following fda type a meeting to discuss fitusiran program in hemophilia

Nov 09 2017

BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06

* Alnylam Pharmaceuticals reports third quarter 2017 financial results and highlights recent period activity

Nov 07 2017

BRIEF-Alnylam initiates ENVISION Phase 3 clinical study with givosiran

* Alnylam initiates ENVISION Phase 3 clinical study with givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias (AHPs)

Nov 07 2017

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

Nov 06 2017

Alnylam RNAi drug reverses progress of rare fatal disease: study

More than half of patients with a rare, rapidly progressing often fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study presented on Thursday.

Nov 02 2017

Earnings vs. Estimates